Biogen - International Biopharmaceutical Industry

news

Biogen seeking more information in investigation of Aduhelm patient’s death

Aduhelm has come under intense scrutiny since the Food and Drug Administration's controversial June approval of the drug, the first new Alzheimer's treatment in decad...

26 November 2021 news Aduhelm | Alzheimer

Continue Reading →

news

With approval plans underway, Lilly’s next move is to test its Alzheimer’s drug against Biogen’s

With few treatment options and millions of patients in the U.S. alone, Alzheimer's has long been one of the biggest targets for drug developers. Yet, the disease has...

29 October 2021 news Aduhelm | Alzheimer

Continue Reading →

news

Biogen’s closely watched ALS drug comes up short in late-stage study

An experimental drug for amyotrophic lateral sclerosis missed the main goal of a late-stage clinical trial, marking another setback in attempts to treat the debilitat...

22 October 2021 news ALS | Biogen

Continue Reading →

news

Hint of benefit in Alzheimer’s drug study fuel stock surge for Swiss biotech

A small clinical trial of a once-failed Alzheimer's drug offered tantalizing but inconclusive hints of benefit, propelling shares in its biotech maker higher by more ...

3 September 2021 news Alzheimer | Biogen

Continue Reading →

news

Lilly, preparing Alzheimer’s drug plans, forms new neuroscience unit in company restructure

After numerous setbacks in Alzheimer's disease, Lilly has high hopes for a breakthrough with donanemab. When the FDA controversially approved Biogen's Aduhelm in June...

20 August 2021 news Aduhelm | Alzheimer

Continue Reading →

news

HHS watchdog to review FDA accelerated approval process after Aduhelm controversy

The U.S. health department's inspector general will review how the Food and Drug Administration grants accelerated approvals of new drugs, announcing a broad investig...

13 August 2021 news Aduhelm | Alzheimer

Continue Reading →

Current Edition

Upcoming Events

Advertisement

Biogen seeking more information in investigation of Aduhelm patient’s death

With approval plans underway, Lilly’s next move is to test its Alzheimer’s drug against Biogen’s

Biogen’s closely watched ALS drug comes up short in late-stage study

Hint of benefit in Alzheimer’s drug study fuel stock surge for Swiss biotech

Lilly, preparing Alzheimer’s drug plans, forms new neuroscience unit in company restructure

HHS watchdog to review FDA accelerated approval process after Aduhelm controversy

International Biopharmaceutical Industry